- Research article
- Open Access
Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy
BMC Cancer volume 19, Article number: 478 (2019)
There were few reports of postoperative radiotherapy (PORT) in stage pIII-N2 Non-small-cell Lung Cancer (NSCLC) patients receiving pneumonectomy followed by adjuvant chemotherapy. This study aims to evaluate safety and efficacy of PORT among these patients.
Between Jan. 2004 and Dec. 2015, stage pIII-N2 NSCLC patients receiving pneumonectomy and adjuvant chemotherapy with or without PORT in our institution were retrospectively reviewed.
Totally 119 patients were included, 32 patients receiving adjuvant chemotherapy and PORT (PORT group) and 87 receiving adjuvant chemotherapy alone (Control group). There were more patients with non-R0 resection in PORT group than Control group (25% vs. 8%, p = 0.031). In PORT group, ≥Grade 2 radiation-induced pneumonitis was 2/32. No severe radiation-related heart injury was observed. There was no PORT-related death. Of all patients, median follow-up time was 25 months. Median overall survival time (mOS) and median disease-free survival time (mDFS) were 46 months and 15 months, respectively. The PORT group had significantly better OS (not reached vs. 34 months, p = 0.003), DFS (19 months vs. 13 months, p = 0.024), local recurrence free survival (LRFS, p = 0.012), and distant metastasis free survival (DMFS, p = 0.047) than the Control group. As for failure pattern, PORT significantly reduced local regional failure rate (39.1% vs. 15.6%, p = 0.016). In subgroup analysis, patients with R0 resection (n = 104), OS and LRFS in PORT group were significantly longer, and PORT tended to increase DFS and DMFS.
For patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy, PORT can improve OS, DFS, LRFS and DMFS with tolerable toxicity.
For patients with stage pIII-N2 non-small-cell lung cancer (NSCLC) after surgery followed by adjuvant chemotherapy, postoperative radiotherapy (PORT) is a major treatment modality. Recently, a large number of retrospective studies have confirmed that 5-year overall survival (OS) could be improved by 5–6% with the application of modern radiation techniques such as three-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiation therapy (IMRT) [1,2,3,4]. However, most patients in these studies received lobectomy. At present, pneumonectomy is still an important therapeutic option for central, giant mass or tumors involving main bronchus or large blood vessels [5,6,7], which may bring benefits to survival . As respiratory and circulatory system load (such as right ventricle) increases after pneumonectomy [5, 9], tolerance to radiation-induced pneumonitis, esophagitis and cardiac toxicity decreases after radiotherapy. Therefore, for patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy, safety and efficacy of PORT needs to be evaluated. The study aimed to evaluate the safety and efficacy of PORT for patients with stage pIII-N2 NSCLC after pneumonectomy and adjuvant chemotherapy.
Between Jan. 2004 and Dec. 2015, patients with stage pIII-N2 NSCLC who underwent pneumonectomy followed by adjuvant chemotherapy with or without PORT were retrospectively analyzed. Clinical features included: age, performance status, sex, smoking index, lung function, etc. Smoking index was defined as the number of cigarettes smoked per day plus years of smoking; preoperative pulmonary function was assessed by the absolute value of FEV1 and the percentage of FVC. Pathological information included: site of primary tumor, pathological type, tumor size, pathological stage, invasion of large vessels, lymphatic vascular invasion (LVSI), number of (positive) lymph nodes dissected and margin status. Invasion of large vessels was defined as the invasion of aorta, trunk of the pulmonary artery, superior and inferior vena cava, and any other intra-pericardial vessels.
All patients received pneumonectomy and mediastinal lymph node dissection. Adjuvant chemotherapy consisted of 4 cycles of platinum-based doublet chemotherapy. PORT was performed according to resection status, KPS and patients’ wills with 6MV x-ray linear accelerator using IMRT or 3D-CRT techniques. Clinical target volume (CTV) included bronchial stump, ipsilateral hilum, mediastinum with or without supraclavicular area. Radiation dose was 50–60 Gy given by 1.8–2.0 Gy per fraction. Percentage of contralateral lung volume receiving at least 20Gy (V20) was restricted as equal to or less than 10% and mean dose of the contralateral lung was limited as equal to or less than 8Gy.
Toxicity and outcome assessment
Radiation toxicities were evaluated by Common Terminology Criteria for Adverse Events Version 4.0(CTCAE). Survival durations were defined as the time from surgery to the date of death due to any cause (overall survival, OS), to treatment failure or death due to any cause (disease free survival, DFS); to locoregional failure or death due to any cause (local recurrence free survival, LRFS) or to distant metastasis or death due to any cause (distant metastasis free survival, DMFS).
Data analysis was performed by SPSS statistical software (version 20.0; SPSS Inc., Chicago, IL). Chi-square test was used for categorical variables. Normality test for continuous variables was performed with Kolmogorov-Smirnov method. Student-t test was used to assess normal distribution variables, and Mann-Whitney U test was used for non-normal distribution variables. Kaplan-Meier method was performed to calculate survival data, and differences between groups were determined by log-rank test. A p-value of < 0.05 was considered as statistical significance.
Patients and tumor characteristics
A total of 119 patients were enrolled. Characteristics were presented in Table 1. All patients had a Karnofsky performance score over 80. The median age was 53 years (range, 27 to 73 years), and 84% (100/119) were male. 78.2% (93/119) underwent left lung resection, and squamous cell carcinoma (74/119, 62.2%) was the main histologic type. According to AJCC 7th Staging System, most patients were in pathological stage IIIA (104/119, 87.4%). All patients received pneumonectomy and mediastinal lymph node dissection. R0-, R1- and R2-resection were 104/119 (87.4%), 9/119 (7.6%) and 6/119 (5%), respectively.
After pneumonectomy, 32 patients (26.9%) received adjuvant chemotherapy and radiotherapy (PORT group), while 87 patients (73.1%) underwent adjuvant chemotherapy alone (Control group). Among 32 patients in PORT group, 27 received chemotherapy followed by PORT. The other 5 received PORT followed by chemotherapy. Baseline characteristics between the two groups were comparable (p > 0.05), except that the rate of non-R0 resection (R1 and R2) was significantly higher in PORT group than in Control group (25% vs. 8%, p = 0.031). In PORT group, 25 patients (78.1%) had IMRT and 7 patients (21.9%) had 3D-CRT. The median prescription dose was 54 Gy (range, 30 to 66Gy), and median percentage of contralateral lung volume receiving at least 20Gy (V20) was 4.75% (range, 1–11.5%).
Toxicities of radiotherapy
93.75% (30/32) patients completed PORT (completing dose above 50Gy) after pneumonectomy. One patient terminated radiotherapy at 30Gy due to chest pain, and the other patient terminated radiotherapy at 40Gy due to brain metastases. Grade 2 and grade 3 radiation pneumonitis was observed in one patient each, and the V20 of the two patients was 8.86 and 7%, respectively. There was no grade 4/5 radiation pneumonitis in PORT group. Grade 2 radiation esophagitis was observed in 10 of 32 (31.3%) patients, and no ≥ grade 3 radiation esophagitis occurred. No patients suffered significant heart damage during follow-up.
For all patients, the median follow-up time was 25 months (range, 2–160 months). The median survival time (MST) was 46 months, and the 1-, 3- and 5-year OS were 87, 53.8 and 46.3%, respectively. The median DFS was 15 months, and the 1-, 3- and 5-year DFS were 55, 28.5 and 24.5%, respectively. Besides, the median LRFS and DMFS were 25 months and 19 months, respectively (Table 2).
The median OS in PORT group was significantly improved compared with Control group (Fig. 1a), which was not reached and 34 months, respectively (p = 0.003). The Fig. 1b shows the DFS curves for the both groups. The median DFS were 19 months in PORT group and 13 months in Control group, respectively (p = 0.024). There were significant differences in LRFS and DMFS between PORT group and Control group as shown in Fig. 1c and d. The median LRFS were 95 months and 22 months (p = 0.012), respectively. The median DMFS were 47 months and 17 months (p = 0.047), respectively. In subgroup analysis, statistically improved OS and LRFS were also found between the two groups in patients with R0 resection. The median OS was not reached versus 34 months (p = 0.032) and the median LRFS was 95 months versus 22 months (p = 0.033), respectively. PORT tended to improve DFS (p = 0.111) and DMFS (p = 0.179), with no crossing of the curves. For patients with non-R0 resection (8 in PORT group, and 7 in Control group), the OS, DFS and LRFS in PORT group was also significantly improved. While there was no significant difference of DMFS between the two groups (p = 0.087).
Eighty-two relapses (68.9%) were found. Of all the relapses, 58 (48.7%) were distant metastasis, and 39 (32.8%) were local-regional recurrence. Distant metastasis was the main failure pattern in both PORT group and Control group (50.0% vs. 48.3%, p = 0.867). However, failure occurred in local-regional site in PORT group was significantly lower than in Control group (15.6% vs. 39.1%, p = 0.016) (Table 3). Of the 5 patients with local-regional failure in PORT group, 4 were out of radiation field, and 1 (disrupted at 30Gy because of chest pain) within radiation field.
For stage pIII-N2 NSCLC after pneumonectomy followed by adjuvant chemotherapy, the results showed good compliance and safety of PORT without any severe radiation pneumonitis and esophagitis. Compared with the control, PORT significantly improved OS, DFS, LRFS and DMFS, although there were more patients with R1/R2 resection in PORT group. To our knowledge, this is the first study focusing on the safety and efficacy of PORT for stage pIII-N2 NSCLC after pneumonectomy followed by chemotherapy.
Safety of radiotherapy after pneumonectomy is the most important concern in clinical practice. Pneumonectomy leads to great change on cardiopulmonary function. The removal of an entire lung decreases the tolerance to radiotherapy and amplifies potential risks, leading to few application of radiotherapy. In our study, 32 patients (26.9%) received PORT. In 104 patients with R0 resection, 24 cases (23.1%) were in the PORT group, which was consistent with previous reports (less than 25%) [5, 10, 11], and was significantly less than patients receiving PORT after lobectomy (43.4%) . The postoperative residual tumor in gross or positive margin in microscopy was an important indication of PORT. In this study, although more patients (8/15, 53.3%) with non-R0 resection received PORT comparing with those with R0 resection (23.1%), there were still nearly half of the patients not receiving PORT, which revealed the concern on safety of PORT in both physicians and patients.
Contrary to concerns on the risks of PORT after pneumonectomy, this study showed that PORT was well tolerant with high compliance (completion rate of 93.8%). Only one patient (3.1%) suffered grade 2 radiation pneumonitis and one patient (3.1%) suffered grade 3 radiation pneumonitis, while no severe radiation pneumonitis (≥ grade 4) occurred. The incidence of ≥ grade 2 radiation pneumonitis in this study was significantly lower compared with the toxicities in previous studies of radical chemoradiotherapy (10–35%) [13,14,15,16], and previous studies of radiotherapy or chemoradiotherapy after lobectomy [17, 18]. Bradly  reported ≥grade 3 radiation pneumonitis with the incidence rate of 6% in 88 patients receiving adjuvant chemotherapy and concurrent radiotherapy after surgery, while pneumonectomy accounted for 14%. Besides, Zhao  demonstrated that the incidence of ≥grade 2 radiation pneumonitis was 13% after lobectomy, and 0% after pneumonectomy, which verified the safety of radiotherapy after pneumonectomy. Zhao believed that strict lung dose constraint and experienced beam arrangement (outside pulmonary parenchyma) were all protective and beneficial factors, which might be the reason for no serious radiation pneumonitis after pneumonectomy. In addition, in our research, low prescription dose (median dose 54Gy) and modern techniques could effectively reduce the volume and dose of the contralateral lung (median V20 4.75%), which was also an important reason for the low occurrence of radiation pneumonitis. Radiation esophagitis was another common side effect of radiotherapy. However, large-scaled analysis showed that the rate of ≥grade 3 radiation esophagitis was only 4% in NSCLC patients after postoperative chemotherapy and radiotherapy . Although there were nearly 1/3 of patients suffering grade 2 radiation esophagitis in our study, no severe radiation esophagitis was noted, which may be related to the precise techniques and careful protection of normal tissue in radiotherapy after pneumonectomy. Therefore, with careful assessment of pulmonary function, reasonable prescription dose, contralateral lung dose limitation and beam arrangement, radiotherapy after pneumonectomy was safe and feasible for stage pIII-N2 patients.
In recent years, a number of retrospective studies have shown survival benefits brought by PORT in stage pIII-N2 NSCLC patients after surgery. However, most patients in these studies received lobectomy. As reported, only a few patients received pneumonectomy with the rate of 16% in Corso’s study , 8.3% in Robinson’s study , 10.8% in Hui’s study , 27.4% in Shen’s study , and highest in the ANITA study, which was only 36.9% . Therefore, the benefit of PORT to survival in patients receiving pneumonectomy is not clear and still needs to be evaluated. Our study showed that PORT significantly improved OS, DFS, LRFS and DMFS in stage pIII-N2 NSCLC patients receiving pneumonectomy and adjuvant chemotherapy, although there were more patients with R1/R2 resection in PORT group. In subgroup analysis of patients with R0 resection, PORT was significantly related to better OS and LRFS, and DFS and DMFS in the PORT group trended to be improved. Even in patients with R1/R2 resection, there was a positive correlation between OS and PORT.
Local-regional recurrence is common in stage pIII-N2 NSCLC patients receiving surgery alone . PORT could increase local-regional control. However, the important premise of transforming improved local-regional control into better OS was the effective prevention of distant metastasis by adjuvant chemotherapy. Thus, we enrolled patients with adjuvant chemotherapy. A meta-analysis showed that some prospective studies failed to show efficacy of PORT in improving overall survival without adjuvant chemotherapy . On the other hand, a large sample retrospective analysis from national cancer database in the United States showed that the implementation of PORT on the basis of adjuvant chemotherapy, could prolong patients’ median OS by 5 months, and could increase the absolute 5-year survival rate by 5% (39.3% vs 34.8%, p = 0.014, 4]. Additionally, less side effects of chemotherapy and radiotherapy in patients with both R0 resection and non-R0 resection had positive impact on survival. Previous randomized trials showed that ≥grade 3 adverse events occurred in 91% of patients with postoperative concurrent chemoradiotherapy , which was significantly higher than that of patients treated with chemotherapy and radiotherapy. A recent retrospective study revealed that the OS in patients, with R0, R1 or R2 resection, receiving chemotherapy and radiotherapy was higher than those receiving concurrent chemoradiotherapy, although the survival benefits were not statistically significant in patients with R1/R2 resection . The researchers believed that toxicities of concurrent chemoradiotherapy counteract the benefits. Therefore, pneumonectomy followed by chemotherapy and radiotherapy was a suitable mode of treatment for stage pIII-N2 NSCLC patients in order to ensure safety of surgery and adjuvant treatment.
As for failure mode, this study showed that distant metastasis was still the main reason (48.7%) of failure after pneumonectomy, followed by local-regional recurrence (32.8%). The result was consistent with the failure patterns in previously published studies, which showed that distant metastasis being the main cause of failure in stage pIII-N2 NSCLC after surgery (about 37–51%), and local-regional recurrence rate accounting for 10–35% [21, 25,26,27]. In several case-controlled studies enrolling stage pIII-N2 patients, PORT significantly reduced local and regional recurrence rates, compared with non-radiotherapy groups. In the ANITA study , local-regional recurrence occurred in 25.7% of patients, which was significantly reduced to 14.6% after combined radiotherapy. In the previous study in our center , 30.2% of locoregional recurrence occurred in the PORT group while 39.2% in patients without PORT (p = 0.025). In this study, for patients receiving pneumonectomy, PORT also achieved a significant reduction in local-regional failure compared with patients received adjuvant chemotherapy alone (15.6% vs. 39.1%, p = 0.016). Moreover, PORT could effectively reduce local-regional recurrence in patients after R0 resection or non-R0 resection, although the difference was not statistically significant (57.1%vs. 37.5%, p = 0.405) in those with non-R0 resection as small sample size (15 cases). In addition, local-regional recurrence in PORT group mostly occurred out of the radiation field (in-filed 1/5 vs. out-of filed 4/5), which also suggested the effective local-regional control of PORT. In summary, distant control still needed to be highlighted for stage pIII-N2 patients as NSCLC is a highly malignant tumor. On condition of effective prevention of chemotherapy in distant metastasis, radiotherapy could reduce local-regional recurrence and further improve survival.
Lobectomy combining with adjuvant chemotherapy and radiotherapy had showed median OS of 20–48 months, and 5-year OS of 25–61.3% for stage pIII-N2 NSCLC [3, 21, 26,27,28,29]. In the INT0139 study, stage pIII-N2 patients receiving chemotherapy and radiotherapy after pneumonectomy approached the median OS of 18.9 months, and the 5- year OS of 21.9% , while 5- year OS was usually lower than 20% in other studies [11, 27, 30, 31]. In this study, the median OS was 46 months and 5- year OS was 46.3%, which was similar to the prognosis of patients after lobectomy and significantly better than patients after pneumonectomy. The reasons for better prognosis in this study were as follows. Firstly, patients who died during peri-operative period were excluded. In previously reported studies, the mortality rate was high after pneumonectomy, which was about 6–20% within 30 days, and up to 25% within 6 months in some studies [5, 9]. In the INT0139 study, 14/54 died of postoperative complications after pneumonectomy . Secondly, only patients receiving adjuvant chemotherapy after pneumonectomy were enrolled in this study. Thirdly, in this study, KPS scores in all patients were more than 80, and the preoperative pulmonary function approached a median FEV1 of 2.36 L. Assessment of the cardiopulmonary function was necessary before pneumonectomy. Some studies have demonstrated that patients with at least 2 L of preoperative FEV1 could tolerate pneumonectomy .
There were some limitations in this study. Firstly, as a retrospective, single-center based study, there might be selective bias in enrollment. Secondly, radiation induced heart injury was evaluated by heart related symptoms instead of routine ECG and echocardiography, which might lead to underestimating side effects of the heart. Thirdly, in this article, only patients who could tolerate pneumonectomy and some cycles of chemotherapy were included, which might underestimate the potential harm of pneumonectomy. However, we aimed to focus to this group of people with high KPS score and survived chemotherapy. Finally, although the clinical characteristics between PORT group and Control group were comparable except that non-R0 resection rate was higher in the former, the number of patients in the PORT group was much lower than the control group (32 patients vs. 87 patients), which might greatly weaken our findings and conclusions. Despite these limitations, this is the largest population based study exploring safety and efficacy of PORT in stage pIII-N2 NSCLC patients after pneumonectomy and adjuvant chemotherapy, which can provide high reference and guidance for PORT of stage pIII-N2 NSCLC after pneumonectomy.
For patients with stage pIII-N2 NSCLC after pneumonectomy followed by chemotherapy, PORT can improve OS, DFS, LRFS and DMFS with tolerable toxicity, which makes PORT be a preferred adjuvant treatment option. Further validation is expected in the future.
Three-dimensional conformal radiotherapy
- CTCAE 4.0:
Common Terminology Criteria for Adverse Events Version 4.0
Clinical target volume
Disease free survival
Distant metastasis free survival
Intensity modulated radiation therapy
Local recurrence free survival
Lymphatic vascular invasion
Median disease-free survival time
Median overall survival time
median survival time
Non-small-cell lung cancer
Corso CD, Rutter CE, Wilson LD, et al. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol. 2015;10:148–55. https://doi.org/10.1097/JTO.0000000000000406.
Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. J Thorac Oncol. 2013;8:940–6. https://doi.org/10.1097/JTO.0b013e318292c53e.
Mikell JL, Gillespie TW, Hall WA, et al. Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. J Thorac Oncol. 2015;10:462–71. https://doi.org/10.1097/JTO.0000000000000411.
Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015;33:870–6. https://doi.org/10.1200/JCO.2014.58.5380.
Ramnath N, Demmy TL, Antun A, et al. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting survival. Ann Thorac Surg. 2007;83:1831–6. https://doi.org/10.1016/j.athoracsur.2006.12.036.
Bjork VO, Carlens E. The prevention of spread during pulmonary resection by the use of a double-lumen catheter. J Thorac Surg. 1950;20:151–7.
Sugarbaker DJ, Haywood-Watson RJ, Wald O. Pneumonectomy for non-small cell lung Cancer. Surg Oncol Clin N Am. 2016;25:533–51. https://doi.org/10.1016/j.soc.2016.02.012.
Hillinger S, Weder W. Extended surgical resection in stage III non-small cell lung Cancer. Controversies in Treatment of Lung Cancer. 2010;42:115–21. https://doi.org/10.1159/000262466.
Melloul E, Egger B, Krueger T, et al. Mortality, complications and loss of pulmonary function after pneumonectomy vs. sleeve lobectomy in patients younger and older than 70 years. Interact Cardiovasc Thorac Surg. 2008;7:986–9. https://doi.org/10.1510/icvts.2008.182279.
Ma QL, Guo YQ, Shi B, et al. For non-small cell lung cancer with T3 (central) disease, sleeve lobectomy or pneumonectomy? J Thorac Dis. 2016;8:1227–33. https://doi.org/10.21037/jtd.2016.04.60.
Eichhorn F, Storz K, Hoffmann H, et al. Sleeve pneumonectomy for central non-small cell lung cancer: indications, complications, and survival. Ann Thorac Surg. 2013;96:253–8. https://doi.org/10.1016/j.athoracsur.2013.03.065.
Hui Z, Dai H, Liang J, et al. Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. Thorac Cancer. 2015;6:346–53. https://doi.org/10.1111/1759-7714.12186.
Barriger RB, Fakiris AJ, Hanna N, et al. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys. 2010;78:1381–6. https://doi.org/10.1016/j.ijrobp.2009.09.030.
Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006;65:1075–86. https://doi.org/10.1016/j.ijrobp.2006.01.051.
Liang J, Bi N, Wu S, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28:777–83. https://doi.org/10.1093/annonc/mdx009.
Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer. 2008;59:232–9. https://doi.org/10.1016/j.lungcan.2007.08.010.
Bradley JD, Paulus R, Graham MV, et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the radiation therapy oncology group--RTOG 9705. J Clin Oncol. 2005;23:3480–7. https://doi.org/10.1200/JCO.2005.12.120.
Zhao L, Ji W, Ou G, et al. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. Lung Cancer. 2012;77:326–30. https://doi.org/10.1016/j.lungcan.2012.03.017.
Francis S, Orton A, Stoddard G, et al. Sequencing of postoperative radiotherapy and chemotherapy for locally advanced or incompletely resected non-small-cell lung Cancer. J Clin Oncol. 2018;36:333–41. https://doi.org/10.1200/JCO.2017.74.4771.
Shen W, Ji J, Zuo Y, et al. Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial. Radiother Oncol. 2014;110(1):120–5. https://doi.org/10.1016/j.radonc.2013.10.008.
Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine international Trialist association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701. https://doi.org/10.1016/j.ijrobp.2008.01.044.
Rube C, Nguyen TP, Fleckenstein J, Niewald M. Postoperative radiotherapy in localized non-small cell lung cancer. Lung Cancer. 2001;33:S29–33.
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257–63.
Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60. https://doi.org/10.1093/jnci/djr325.
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86. https://doi.org/10.1016/S0140-6736(09)60737-6.
Lee HW, Noh OK, Oh YT, et al. Radiation therapy-first strategy after surgery with or without adjuvant chemotherapy in stage IIIA-N2 non-small cell lung Cancer. Int J Radiat Oncol Biol Phys. 2016;94:621–7. https://doi.org/10.1016/j.ijrobp.2015.11.020.
Dai H, Hui Z, Ji W, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist. 2011;16:641–50. https://doi.org/10.1634/theoncologist.2010-0343.
Zou B, Xu Y, Li T, et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys. 2010;77:321–8. https://doi.org/10.1016/j.ijrobp.2009.05.044.
Legras A, Mordant P, Arame A, et al. Long-term survival of patients with pN2 lung cancer according to the pattern of lymphatic spread. Ann Thorac Surg. 2014;97:1156–62. https://doi.org/10.1016/j.athoracsur.2013.12.047.
Petrella F, Spaggiari L. Therapeutic options following pneumonectomy in non-small cell lung cancer. Expert Rev Respir Med. 2016;10:919–25. https://doi.org/10.1080/17476348.2016.1188694.
Graeter TP, Sebastian B, Bischof M, et al. Analysis of patients unable to undergo adjuvant chemotherapy after surgery in stage IIIA/B non-small cell lung Cancer: will they benefit from mediastinal radiotherapy? Thorac Cardiovasc Surg. 2016;64:501–6. https://doi.org/10.1055/s-0035-1562940.
This work was supported by National key research and development project (2017YFC1311000). The funding body had no role in the design of the study, collection, analysis, and interpretation of data nor in writing the manuscript.
Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College. This is a retrospective study and written human subject consent was unnecessary.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wang, W., Men, Y., Wang, J. et al. Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. BMC Cancer 19, 478 (2019). https://doi.org/10.1186/s12885-019-5692-3
- Non-small-cell lung cancer
- Stage pIII-N2
- Postoperative radiotherapy